Yearend Archives | Iconovo

YEAR-END REPORT JANUARY-DECEMBER 2022

February 8, 2023

Global interest in Iconovo's proprietary inhaler platform ICOpre® - ready to address the world's largest products for Asthma and COPD

BOKSLUTSKOMMUNIKÉ 1 JANUARI – 31 DECEMBER 2022

February 8, 2023

Globalt intresse för Iconovos egenutvecklade inhalatorplattform ICOpre® - redo att addressera världens största produkter för Astma och KOL

BOKSLUTSKOMMUNIKÉ 1 JANUARI – 31 DECEMBER 2021

February 18, 2022

Stora framsteg inom Iconovos tre strategiska verksamhetsområden

DELÅRSRAPPORT 1 JANUARI – 31 DECEMBER 2020

February 17, 2021

50 procents tillväxt 2020 och ambitiösa mål för framtiden

Bokslutskommuniké 1 januari – 31 december 2019

February 14, 2020

Välfinansierade för kraftig tillväxt Nyckeltal kSEK om inget annat anges okt-dec 2019 okt-dec 2018 jan-dec 2019 jan-dec 2018 Nettoomsättning…

BOKSLUTSKOMMUNIKÉ 1 JANUARI – 31 DECEMBER 2018

February 14, 2019

Samtliga Iconovos tre inhalationsplattformar är nu kommersialiserade FJÄRDE KVARTALET I KORTHET Operativt Förstudieprojekt inleddes för…

The information contained in this section of Iconovo AB’s (“Iconovo”) website is restricted and may not be accessed by residents of certain countries based on applicable securities law regulations.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (the ”United States”), Australia, Canada, New Zealand, Hong Kong, Japan, Singapore, South Africa, South Korea, Russia, Belarus and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or securities of Iconovo in any of the above mentioned jurisdictions or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of Iconovo referred to on this website have not been, and will not be, registered under the Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.

All persons residing outside of the above-mentioned jurisdictions who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website or require registration or approval for any acquisition of securities by them. Iconovo assumes no responsibility if there is a violation of applicable law and regulations by any person.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this website.

By clicking ”Confirm” you confirm and certify that:

You are not a resident of or physically present in any of the above jurisdictions or any other restricted jurisdiction; and
you are either:
- a resident of, or physically present in, Sweden;
- if resident or physically present in a Member State of the European Economic Area other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 of the European parliament and of the council; or
- otherwise authorized to access this information pursuant to applicable laws or regulations.